Vivo Bio Tech Limited Announces Q1 FY27 Results; Net Profit Rebounds Sequentially to ₹18.76 Lakhs

Biotechnology services provider Vivo Bio Tech Limited has released its un-audited consolidated financial results for the first quarter of the fiscal year 2026-27, ended June 30, 2026. The company achieved steady top-line growth and turned its bottom-line back into profitability after a challenging conclusion to the previous financial year.

Income Growth Maintained Leg-Over-Leg

During the April-June quarter of 2026, Vivo Bio Tech sustained operational traction across its pre-clinical research and laboratory animal facility platforms.

Revenue Performance: Consolidated revenue from operations stood at ₹1,427.97 lakhs, reflecting a steady minor expansion over the ₹1,420.11 lakhs tracked in the preceding winter quarter ended March 31, 2026. Year-on-year, operational revenue expanded by 14.13% compared to the ₹1,251.16 lakhs recorded in the corresponding quarter of the previous fiscal year.

Consolidated Total Income: Factoring in an other income contribution of ₹5.54 lakhs, total income reached ₹1,433.51 lakhs, showing incremental growth from the ₹1,423.16 lakhs reported in Q4 FY26.

Operating Expenditures and Fixed Costs Expansion

Total consolidated expenses for Q1 FY27 reached ₹1,399.65 lakhs, trending higher due to non-cash charges and elevated procurement:

Procurement & Stocks: The purchase of traded goods rose to ₹286.13 lakhs from ₹277.04 lakhs in the trailing quarter. An inventory accumulation in stock-in-trade and work-in-progress led to a positive credit adjustment of ₹(100.50) lakhs.

Manpower & Support costs: Employees cost remained the largest operational outgo at ₹472.98 lakhs, showing a slight optimization down from ₹488.04 lakhs in Q4 FY26. Administrative expenditure rose to ₹264.11 lakhs.

Capital Allowances & Charges: Depreciation and amortization expenses grew to ₹353.17 lakhs from ₹275.21 lakhs sequentially. Finance costs tracked lower at ₹123.76 lakhs against ₹147.64 lakhs in the preceding quarter.

Sequential Recovery Out of Net Losses

The company reported a Profit Before Tax (PBT) of ₹33.86 lakhs for the quarter, down from ₹85.56 lakhs in the preceding quarter before accounting for adjustments, but up from the final adjusted PBT of ₹25.11 lakhs in Q4 FY26.

After provisioning ₹24.83 lakhs for current income tax outlays and capturing a deferred tax credit of ₹(9.74) lakhs, total tax expense for the period settled at ₹15.10 lakhs.

Vivo Bio Tech closed the quarter with a consolidated net profit of ₹18.76 lakhs, marking a distinct visual recovery over the deep net loss of ₹(516.27) lakhs recorded in the previous quarter, which had been burdened by large deferred tax charges and prior period restatements. On a year-on-year basis, net profit compressed from the ₹133.71 lakhs delivered in Q1 FY26 due to the higher depreciation and overhead mix.

On a paid-up share capital base of ₹2,219.06 lakhs (shares at face value of ₹10 each), basic and diluted earnings per share (EPS) clawed back into positive territory at ₹0.08 for the quarter, recovering from the negative ₹(2.52) basic EPS seen in the March quarter.

Shares of VIVO BIO TECH LTD. was last trading in BSE at Rs. 25.19 as compared to the previous close of Rs. 23.57. The total number of shares traded during the day was 108921 in over 371 trades.

The stock hit an intraday high of Rs. 25.67 and intraday low of 23.70. The net turnover during the day was Rs. 2728048.00.

Source : Equity Bulls

Keywords

VIVOBIOTECH INE380K01017 Biotechnology Q1FY27 Q1FY2027 ResultUpdate